These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12437510)

  • 1. Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease.
    Salam AM; Suwaidi JA
    Expert Opin Investig Drugs; 2002 Nov; 11(11):1645-58. PubMed ID: 12437510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
    Vorchheimer DA; Badimon JJ; Fuster V
    JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I.
    Cannon CP
    Clin Cardiol; 2003 Aug; 26(8):358-64. PubMed ID: 12918637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
    Chew DP; Bhatt DL; Sapp S; Topol EJ
    Circulation; 2001 Jan; 103(2):201-6. PubMed ID: 11208677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR
    Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.
    Roffi M; Mukherjee D; Chew DP; Bhatt DL; Cho L; Robbins MA; Ziada KM; Brennan DM; Ellis SG; Topol EJ
    Circulation; 2002 Dec; 106(24):3063-7. PubMed ID: 12473552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous glycoprotein IIb/IIIa antagonists: their benefits, problems and future developments.
    Curtin R
    Curr Pharm Des; 2004; 10(14):1577-85. PubMed ID: 15134556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral GPIIb/IIIa antagonists: what went wrong?
    Cox D
    Curr Pharm Des; 2004; 10(14):1587-96. PubMed ID: 15134557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
    Murphy J; Wright RS; Gussak I; Williams B; Daly RN; Cain VA; Pieniaszek HJ; Sy SK; Ebling W; Simonson K; Wilcox RA; Kopecky SL
    Am J Cardiovasc Drugs; 2003; 3(2):101-12. PubMed ID: 14727937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?
    Quinn MJ; Plow EF; Topol EJ
    Circulation; 2002 Jul; 106(3):379-85. PubMed ID: 12119257
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
    Heitzer T; Ollmann I; Köke K; Meinertz T; Munzel T
    Circulation; 2003 Aug; 108(5):536-41. PubMed ID: 12874186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa inhibitors in unstable angina.
    Theroux P
    Curr Opin Cardiol; 1997 Sep; 12(5):447-52. PubMed ID: 9352171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].
    Patti G; Fossati C; Manzoli A; D'Ambrosio A; Abbate A; Montesanti R; Di Sciascio G
    Clin Ter; 2000; 151(4):301-6. PubMed ID: 11107681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease.
    Lefkovits J; Topol EJ
    Eur Heart J; 1996 Jan; 17(1):9-18. PubMed ID: 8682137
    [No Abstract]   [Full Text] [Related]  

  • 20. Is there a role for oral blockade of platelet glycoprotein IIb/IIIa receptors in coronary and cerebrovascular disease?
    Salam AM
    Expert Opin Investig Drugs; 2003 Oct; 12(10):1709-12. PubMed ID: 14519089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.